Supported by
| Poster Title |
|---|
| AL amyloidosis |
| Systemic AL amyloidosis associated with multiple myeloma: real-world experience from a Tunisian hematology center Rahal Amira, Tunisia |
| CAR T cells / Transplantation |
| Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma: Experience of the P.A. Herzen Moscow Oncology Research Institute (2020–2025) Vladimir Lunin, Israel |
| EVALUATING NUTRITIONAL INDICATORS AND TIME TO NEXT TREATMENT (TTNT) IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING STEM CELL TRANSPLANT: REAL WORLD DATA Background Andrea Victoria Pacheco Sanchez, Mexico |
| Impact of Outpatient CAR T Cell Monitoring on Healthcare Utilization in Multiple Myeloma Nadine Abdallah, USA |
| REAL-WORLD EXPERIENCE WITH EARLY LINE CILTACABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA Brandon Kale, USA |
| TRIAL IN PROGRESS: QUINTESSENTIAL-2—A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) EXPOSED TO LENALIDOMIDE Eyal Lebel, Israel |
| Immunotherapy |
| A Case of Elranatamab Induced Primary Adrenal Insufficiency Ebrar Uzunabdullah, Turkey |
| REAL-WORLD SAFETY AND EARLY OUTCOMES OF TECLISTAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SINGLE-CENTER EXPERIENCE FROM GUATEMALA Pablo Jose Paredes Flores, Guatemala |
| WHAT COMES NEXT AFTER IMMUNE THERAPY IN MULTIPLE MYELOMA? REAL-WORLD SEQUENCING AFTER CAR-T AND BISPECIFIC ANTIBODIES Jorge Arturo Hurtado Martinez, Canada |
| Multiple myeloma |
| A case report of relapsed multiple myeloma with concurrent infection of aspergillosis Jiantuo Liu, China |
| A Rare Diagnostic Challenge: IgM Kappa Multiple Myeloma Mimicking Vertebral Metastasis After Prostate Cancer Melis Bektaş, Turkey |
| A SILENT MASS THAT SPEAKS FIRST: INTRACRANIAL PLASMACYTOMA AS THE INITIAL PRESENTATION OF MULTIPLE MYELOMA IN ELDERLY WOMAN Ana Qose, Albania |
| Chronic myeloid leukemia with multiple myeloma in a single Tunisian patient Fatma Turki, Tunisia |
| COEXISTENCE OF MULTIPLE MYELOMA AND MYELOFIBROSIS: IS THERE A CORRELATION? Rim Frikha, Tunisia |
| COMPARISON OF SERUM-BASED METHODS AND BONE MARROW NEXT GENERATION FLOW CYTOMETRY FOR DISEASE MONITORING IN MULTIPLE MYELOMA: IS IT ALWAYS NECESSARY TO PERFORM BOTH? Ana Catarina Fonseca, Portugal |
| Concurrent Essential Thrombocythemia and Multiple Myeloma Presenting With Marked Thrombocytosis at Diagnosis: A Rare Case Report Gulsum Akgun Cagliyan, Turkey |
| DEVELOPMENT OF AN STR PANEL FOR SCREENING OF 1P32.3 DELETION IN MULTIPLE MYELOMA Natalya Risinskaya, Russia |
| DEVELOPMENT OF IN VITRO MODEL SYSTEM FOR FUNCTIONAL ASSESSMENT OF IMMUNOTHERAPY EFFICACY IN MULTIPLE MYELOMA Dominika Balcerowska, Denmark |
| EXTERNAL VALIDATION OF A FIRTH-PENALIZED EASIX MORTALITY MODEL ACROSS FOUR INDEPENDENT LATIN AMERICAN AND ONE UNITED STATES HISPANIC-BASED COHORTS OF PATIENTS WITH MULTIPLE MYELOMA Gledy Jimenez Tornero, Peru |
| EXTERNAL VALIDATION OF THE SAVED-VTE SCORE IN A CANADIAN REGIONAL CANCER CENTRE COHORT: A REAL-WORLD ANALYSIS Anthony Naassan, Canada |
| EXTRAMEDULLARY MULTIPLE MYELOMA: CLINICAL EXPERIENCE FROM A SINGLE CENTER Yasmine Benjelloun, Morocco |
| GEOGRAPHIC PATTERNS IN HEALTHCARE BURDEN OF MULTIPLE MYELOMA IN SPAIN: TRENDS IN HOSPITALIZATION AND MORTALITY (2016–2023) Ane Brieva López, Spain |
| IgD-λ Multiple Myeloma: A Case Report and Literature Review Haiqin Zhang, China |
| Infection Incidence, Timing, and Predictors in Newly Diagnosed Multiple Myeloma: A Real-World Retrospective Cohort Study Ozlem Candan, Turkey |
| LAGOON (OP-115): A NON-INTERVENTIONAL STUDY OF MELPHALAN FLUFENAMIDE (MELFLUFEN) PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM) IN SPAIN ACCORDING TO THE APPROVED LABEL Enrique M. Ocio, Spain |
| LENALIDOMIDE-INDUCED CUTANEOUS ADVERSE REACTIONS IN MULTIPLE MYELOMA: PREVALENCE IN REAL-WORLD CLINICAL PRACTICE Yasmine Moutmir, France |
| Long-term progression-free survival benefit with ciltacabtagene autoleucel (cilta-cel) in standard-risk relapsed/refractory multiple myeloma (RRMM) Salomon Manier, France |
| MAINTAINED RENAL FUNCTION WITH MELFLUFEN THERAPY IN RRMM: RESULTS FROM ANALYSIS OF POOLED CLINICAL DATA Paul G. Richardson, USA |
| MANAGING MULTIPLE MYELOMA IN PATIENTS AGED >84 YEARS: REAL WORLD DATA FROM A SINGLE CENTRE Maria Couto, Ireland |
| MORTALITY OUTCOMES AND CLINICAL RISK FACTORS IN MULTIPLE MYELOMA Ane Brieva López, Spain |
| MUCORMYCOSIS WITH CEREBRAL PARENCHYMAL INVOLVEMENT IN A PATIENT WITH A HISTORY OF AUTOLOGOUS STEM CELL TRANSPLANTATION AND RENAL TRANSPLANTATION Handan Haydaroglu Sahin, Turkey |
| National Evaluation of the 2016 Tunisian Protocol in Transplant-Eligible Multiple Myeloma: A Multicenter Real-World Study Informing the 2024 National Guidelines Faten Kallel, Tunisia |
| NATIONAL TRENDS IN MULTIPLE MYELOMA RELATED HOSPITALIZATIONS IN SPAIN (2016–2023): INCREASING BURDEN AND REDUCED IN-HOSPITAL MORTALITY Ane Brieva López, Spain |
| Novel Therapeutic Approaches in Relapsed/Refractory Multiple Myeloma Following Allogeneic Stem Cell Transplantation: A Case Report Sebnem Izmir, Turkey |
| PERIPHERAL STEM CELL AUTOLOGOUS TRANSPLANTATION WITHOUT CRYOPRESERVATION: SINGLE-CENTER EXPERIENCE FROM THE HEMATOLOGY DEPARTMENT OF ORAN MILITARY HOSPITAL IN THE MANAGEMENT OF MULTIPLE MYELOMA Soumeya Abderrahmani, Algeria |
| POMALIDOMIDE, CYCLOPHOSPHAMIDE, and DEXAMETHASONE in RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SINGLE-CENTER EXPERIENCE Ayşe Uysal, Turkey |
| PROGNOSTIC IMPACT OF BASELINE LABORATORY PARAMETERS ON MORTALITY IN PATIENTS WITH MULTIPLE MYELOMA: A RETROSPECTIVE COHORT STUDY Abdukadir Karismaz, Turkey |
| Real-World Outcomes of Isatuximab-Carfilzomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Single-Center Analysis Using the IMS/IMWG Consensus Genomic Staging María Isabel Peris Feranud, Spain |
| Real-world outcomes of multiple myeloma in patients older than 65 years: a multicenter Tunisian study Nesrine Ben Sayed, Tunisia |
| Real-World Practices of Primary Thromboprophylaxis in Multiple Myeloma: Insights from a Nationwide Survey of Moroccan Hematologists Oumayma Hari, Morocco |
| RESPONSES INDUCED BY CYBORD IN MULTIPLE MYELOMA: OUTCOMES IN THE ABSENCE OF ASCT IN KOSOVA Aferdita Ukimeraj, Kosovo |
| Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients (Pts) with newly diagnosed multiple myeloma (NDMM): analysis of sustained minimal residual disease negativity (MRD neg) in the phase 3 PERSEUS trial Pieter Sonneveld, Netherlands |
| THE REAL-WORLD INFLUENCE OF REGIMEN SELECTION ACROSS SUCCESSIVE LINES OF THERAPY IN MULTIPLE MYELOMA Edgar Ricardo Olivas-Domínguez, Mexico |
| THROMBOTIC RISK STRATIFICATION IN MULTIPLE MYELOMA: PREDICTORS MISSING FROM IMPEDE-VTE SCORE IDENTIFIED IN MOROCCO Siham Belkadi, Morocco |
| Truly Aggressive IgD Myeloma? Excellent Responses from Case Series Siham Belkadi, Morocco |
| UNWANTED VARIATION IN POST-DOSE OBSERVATION FOR SUBCUTANEOUS DARATUMUMAB AND ITS IMPACT ON DAY-UNIT CAPACITY Faye Sharpley, UK |
| Young Multiple Myeloma Patients (30–50 Years): The Depth of Response to First-Line Treatment Predicts Survival in a Single-Center Cohort Based on Real-World Data Esra Pirinççi, Turkey |
| NDMM |
| IMMUNOPHENOTYPIC PROFILES AND ASSOCIATION WITH SURVIVAL AND CLINICAL STAGE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A RETROSPECTIVE STUDY IN RESOURCE-CONSTRAINED SETTINGS Sri Agustini Kurniawati, Indonesia |
| ISATUXIMAB IN COMBINATION WITH BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (ISA-VRD) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS NOT CANDIDATES FOR TRANSPLANTATION: CLINICAL PRACTICE EXPERIENCE IN FIVE HOSPITALS IN ANDALUSIA, SPAIN Maria Esther Clavero Sanchez, Spain |
| SPATIAL IMAGING UNLOCKS THE POTENTIAL OF CHARTING MULTIPLE MYELOMA AND EXTRAMEDULLARY DISEASE Vanessa Desantis, Italy |
| RRMM |
| CHARACTERIZATION AND OUTCOMES OF SPANISH PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE MAJESTEC-1 AND REALITEC STUDIES Eva Rubio Azpeitia, Spain |
| EFFICACY AND DURABILITY OF BELANTAMAB MAFODOTIN PLUS POMALIDOMIDE AND DEXAMETHASONE TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): LONG-TERM FOLLOW-UP OF THE PHASE 3 DREAMM-8 STUDY Suzanne Trudel, Canada |
| Efficacy and Safety of Carfilzomib in Relapsed/Refractory Multiple Myeloma — Single-Center Experience (n=128) Cherifa Guezlane, Algeria |
| INFECTION RATE PROFILE OF ETENTAMIG MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Cesar Rodriguez Valdes, USA |
| KAPOSI SARCOMA DEVELOPMENT DURING THE COURSE OF ELRANATAMAB THERAPY: A CASE REPORT Ayse Salihoglu, Turkey |
| Management of High-Risk Relapsed/Refractory Multiple Myeloma with Combination Chemo-Immunotherapy Leading to Allogeneic Stem Cell Transplantation Sotirios Bristogiannis, Greece |
| Prevention Of Selinexor-Induced Nausea/Vomiting and Diarrhea in First Month of Therapy: A Novel Step-Up Dosing Approach Turgay Ulas, Turkey |
| Rare case of CNS myeloma, successfully treated with intrathecal chemotherapy, selinexor and craniospinal radiotherapy Agata Bruzgul, Lithuania |
| REAL WORLD USE OF MELPHALAN FLUFENAMIDE (MELFLUFEN) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS IN 60 PATIENTS FROM THE SPANISH REGISTRY David Martínez-Campuzano, Spain |
| REAL-WORLD OUTCOMES OF GPRC5D- AND BCMA-TARGETING BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: ACTIVITY FOLLOWING PRIOR BCMA EXPOSURE Dionisios Stoumbos, Greece |
| Smoldering myeloma / MGUS |
| MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE PRESENTING AS MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: REPORT OF TWO CASES Soumeya Abderrahmani, Algeria |
| Patient Experiences and Perspectives on Early Intervention in Smoldering Multiple Myeloma: A Cross-Sectional Survey Study Nadine Abdallah, USA |
| RISK STRATIFICATION AND EARLY PROGRESSION PATTERNS IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE: A 10-YEAR SINGLE-CENTER EXPERIENCE FROM TUNISIA Nesrine Ben Sayed, Tunisia |
| Other |
| INFLUENCE OF ANEMIA ON COGNITIVE FUNCTIONS IN MYELOMA PATIENTS MEASURED BY COMPLEX RECTIONMETER DRENOVAC Marija Stanić Damić, Croatia |
| Plasma cell dyscrasias in HIV-infected patients: a single-center case series Rahal Amira, Tunisia |
